Tigerlily Foundation’s Clinical Trials Program is a transformational initiative to accelerate the delivery of innovative treatments to our patients with a strategic focus on populations that face the highest disparities.
Why do we do this work?
-
We know that most patients of color are not offered trials until their cancers are at a more advanced stage.
-
We know that people of color are underrepresented in clinical trials, yet have the highest mortality rates across multiple disease states
-
We know that this is unacceptable.
-
We are working to transform the clinical trial landscape by building trust and transparency, to achieve equity in clinical trials in this lifetime by holding stakeholders accountable, and to dismantle barriers for patients of color.